Active not recruiting
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)
I3Y-MC-JPBK - ClinicalTrials.gov - NCT02152631
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
How long will I be in the trial?
This trial could take up to 7 months, depending on how you and your tumor respond
Active not recruiting
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)
I3Y-MC-JPBK - ClinicalTrials.gov - NCT02152631
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
How long will I be in the trial?
This trial could take up to 7 months, depending on how you and your tumor respond
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC)
Participant must have a tumor with a KRAS mutation (this will be checked for at screening)
Participant must have received prior chemotherapy
Participants must NOT
Participant must not have an active infection with HIV, Hepatitis B or C, or a history of cardiac arrest
Female participant must not be pregnant or lactating
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Abemaciclib, Erlotinib
Could I receive a Placebo?
no
Enrollment Goal
450
Trial Dates
October 2014 - September 2021
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC)
Participant must have a tumor with a KRAS mutation (this will be checked for at screening)
Participant must have received prior chemotherapy
Participants must NOT
Participant must not have an active infection with HIV, Hepatitis B or C, or a history of cardiac arrest
Female participant must not be pregnant or lactating
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Abemaciclib, Erlotinib
Could I receive a Placebo?
no
Enrollment Goal
450
Trial Dates
October 2014 - September 2021
Trial Phase
3
Not the right fit? Sign up to receive updates on new Non-small Cell Lung Cancer trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Non-small Cell Lung Cancer Resources
